Hakutulokset - Athena Philis‐Tsimikas

Tarkenna hakua
  1. 1
    Glycemic control among Latinos with type 2 diabetes: The role of social-environmental support resources.

    Glycemic control among Latinos with type 2 diabetes: The role of social-environmental support resources. Tekijä Addie L. Fortmann, Linda C. Gallo, Athena Philis‐Tsimikas

    Julkaistu 2011
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Predictors of glycemic control among patients with Type 2 diabetes: A longitudinal study

    Predictors of glycemic control among patients with Type 2 diabetes: A longitudinal study Tekijä Stephen R. Benoit, Regina K. Fleming, Athena Philis‐Tsimikas, Ming Ji

    Julkaistu 2005
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)

    Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use) Tekijä Athena Philis‐Tsimikas, Meryl Brod, Marcus Niemeyer, Ann Marie Ocampo Francisco, Jeffrey Rothman

    Julkaistu 2013
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Peer-Led Diabetes Education Programs in High-Risk Mexican Americans Improve Glycemic Control Compared With Standard Approaches

    Peer-Led Diabetes Education Programs in High-Risk Mexican Americans Improve Glycemic Control Compared With Standard Approaches Tekijä Athena Philis‐Tsimikas, Adelaide Fortmann, Leticia Lleva-Ocana, Chris Walker, Linda C. Gallo

    Julkaistu 2011
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    LDL Isolated From Greek Subjects on a Typical Diet or From American Subjects on an Oleate-Supplemented Diet Induces Less Monocyte Chemotaxis and Adhesion When Exposed to Oxidative Stress

    LDL Isolated From Greek Subjects on a Typical Diet or From American Subjects on an Oleate-Supplemented Diet Induces Less Monocyte Chemotaxis and Adhesion When Exposed to Oxidative... Tekijä Sotirios Tsimikas, Athena Philis‐Tsimikas, Sophoclis P. Alexopoulos, Farhad Sigari, Christian Lee, Peter D. Reaven

    Julkaistu 1999
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4

    Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to O... Tekijä Harpreet S. Bajaj, Björg Ásbjörnsdóttir, Lisbeth Carstensen, Christian Laugesen, Chantal Mathieu, Athena Philis‐Tsimikas, Tadej Battelino

    Julkaistu 2024
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes

    Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes Tekijä Bernard Zinman, Athena Philis‐Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W. Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu

    Julkaistu 2012
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Improvement in Diabetes Care of Underinsured Patients Enrolled in Project Dulce

    Improvement in Diabetes Care of Underinsured Patients Enrolled in Project Dulce Tekijä Athena Philis‐Tsimikas, Chris Walker, Lisa Rivard, Gregory A. Talavera, Joachim O. F. Reimann, Michelle Salmon, Rachel A. Araujo

    Julkaistu 2004
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial

    Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial Tekijä Helena W. Rodbard, Bertrand Cariou, Bernard Zinman, Yehuda Handelsman, Athena Philis‐Tsimikas, Trine Vang Skjøth, Ashma Rana, Chantal Mathieu

    Julkaistu 2013
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes

    Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes Tekijä Wendy Lane, Timothy S. Bailey, Gregg Gerety, Janusz Gumprecht, Athena Philis‐Tsimikas, Charlotte Thim Hansen, Thor S.S. Nielsen, Mark Warren

    Julkaistu 2017
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    Glucose as the Fifth Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a Non-ICU Hospital Setting

    Glucose as the Fifth Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a Non-ICU Hospital Setting Tekijä Addie L. Fortmann, Samantha R. Spierling Bagsic, Laura Talavera, Isabel Maria Garcia, Haley Sandoval, Amiry Hottinger, Athena Philis‐Tsimikas

    Julkaistu 2020
    Hae kokoteksti Hae kokoteksti
    Carta
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (<scp>BEGIN</scp>: <scp>VICTOZA ADD‐ON</scp>)

    A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (<scp>BEGIN</scp>: <scp>VICTOZA ADD‐ON</scp>) Tekijä Chantal Mathieu, Helena W. Rodbard, Bertrand Cariou, Yehuda Handelsman, Athena Philis‐Tsimikas, Ann Marie Ocampo Francisco, Ashma Rana, Bernard Zinman

    Julkaistu 2014
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    Dulce Wireless Tijuana: A Randomized Control Trial Evaluating the Impact of Project Dulce and Short-Term Mobile Technology on Glycemic Control in a Family Medicine Clinic in Northern Mexico

    Dulce Wireless Tijuana: A Randomized Control Trial Evaluating the Impact of Project Dulce and Short-Term Mobile Technology on Glycemic Control in a Family Medicine Clinic in Northe... Tekijä María Cecilia Anzaldo-Campos, Sonia Contreras Contreras, Adriana Carolina Vargas-Ojeda, Rufino Menchaca-Díaz, Addie L. Fortmann, Athena Philis‐Tsimikas

    Julkaistu 2016
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  14. 14
    Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

    Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial Tekijä Chantal Mathieu, Bruce W. Bode, Edward Franek, Athena Philis‐Tsimikas, Ludger Rose, Tina Graungaard, Anne Birk Østerskov, David Russell‐Jones

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  15. 15
    Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes

    Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people... Tekijä Athena Philis‐Tsimikas, Liana K. Billings, Robert S. Busch, Cristóbal Morales, Rakesh Sahay, Natalie Halladin, S Eggert, Kamilla Begtrup, Stewart B. Harris

    Julkaistu 2019
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  16. 16
    Rationale and design of the phase 3a development programme (<scp>ONWARDS</scp> 1–6 trials) investigating once‐weekly insulin icodec in diabetes

    Rationale and design of the phase 3a development programme (<scp>ONWARDS</scp> 1–6 trials) investigating once‐weekly insulin icodec in diabetes Tekijä Athena Philis‐Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David Russell‐Jones, Julio Rosenstock

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  17. 17
    Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme

    Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme Tekijä Richard M. Bergenstal, Athena Philis‐Tsimikas, Carol Wysham, Molly C. Carr, Juliana Bue‐Valleskey, Fady T. Botros, Thomas Blevins, Julio Rosenstock

    Julkaistu 2024
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  18. 18
    Cost‐Effectiveness of Diabetes Case Management for Low‐Income Populations

    Cost‐Effectiveness of Diabetes Case Management for Low‐Income Populations Tekijä Todd Gilmer, Stéphane Roze, William J. Valentine, Katrina Erny-Albrecht, Joshua Ray, D Cobden, L Nicklasson, Athena Philis‐Tsimikas, Andrew Palmer

    Julkaistu 2007
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  19. 19
    Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

    Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial Tekijä Athena Philis‐Tsimikas, David C. Klonoff, Kamlesh Khunti, Harpreet S. Bajaj, Lawrence A. Leiter, M. Hansen, Lone Troelsen, Steen Ladelund, Simon Heller, Thomas R. Pieber

    Julkaistu 2020
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  20. 20
    Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

    Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized,... Tekijä David Russell‐Jones, Bruce W. Bode, Christophe De Block, Edward Franek, Simon Heller, Chantal Mathieu, Athena Philis‐Tsimikas, Ludger Rose, Vincent Woo, Anne Birk Østerskov, Tina Graungaard, Richard M. Bergenstal

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: